ArticleFrontiers in surgery2024
Efficacy and cost-effectiveness analysis of flexible ureteroscopic lithotripsy with TFDS in the treatment of urolithiasis.
Article in Frontiers in surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world effectiveness of total flavonoids fromFrontiers in pharmacology · 2026Article
- Total favonoids of Desmodium Styracifolium relieve renal ischemia-reperfusion injury by suppressing ferroptosis through P53/SLC7A11/GPX4 signaling pathway.Journal of bioenergetics and biomembranes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At present, there is no effective drug to remove residual stones. Total flavonoids of desmodium styracifolium (TFDS) is an innovative traditional Chinese medicine listed in 2022, which can be used to treat ureteral calculi. This study was to explore the effectiveness and economic value of TFDS in the treatment of residual stones after flexible ureteroscopic lithotripsy (FURL). Methods: A total of 161 patients who underwent unilateral ureteroscopic lithotripsy for urinary calculi by the same surgeon in our center from May 2022 to February 2024 were retrospectively included. According to the use of stone-removal drugs after operation, patients were divided into TFDS group and Control group. The residual stones showed by x-ray plain film when the double J tube was removed were compared between the two groups, and the economic benefits of TFDS were analyzed by cost-benefit analysis. Results: The data of 161 patients were collected, including 80 cases in TFDS group and 81 cases in Control group. The SFR rates at the endpoint of follow-up in TFDS group and Control group were 98.75% and 88.88%, respectively. In the subgroup analysis of post-operative residual stones, the stone clearance rate of TFDS was higher (47.62% vs. 18.18%). No obvious adverse events were reported in two groups. The cost/benefit ratio of TFDS was lower (20.43 vs. 32.57). Cost of TFDS was increased by ¥12.97 for each additional unit of total effective rate. Conclusion: The combination of dusting FURL and TFDS can effectively remove the urolithiasis when compared to only FURL, which showed highly economic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.